Literature DB >> 16775223

Therapeutic implications of tumor interstitial fluid pressure in subcutaneous RG-2 tumors.

Yot Navalitloha1, Erica S Schwartz, Elizabeth N Groothuis, Cathleen V Allen, Robert M Levy, Dennis R Groothuis.   

Abstract

Increased interstitial fluid pressure (IFP) in brain tumors results in rapid removal of drugs from tumor extracellular space. We studied the effects of dexamethasone and hypothermia on IFP in s.c. RG-2 rat gliomas, because they could potentially be useful as means of maintaining drug concentrations in human brain tumors. We used dexamethasone, external hypothermia, combined dexamethasone and hypothermia, and infusions of room temperature saline versus chilled saline. We measured tumor IFP and efflux half-time of 14C-sucrose from tumors. In untreated s.c. tumors, IFP was 9.1 +/- 2.1 mmHg, tumor temperature was 33.7 degrees C +/- 0.7 degrees C, and efflux half-time was 7.3 +/- 0.7 min. Externally induced hypothermia decreased tumor temperature to 8.9 degrees C +/- 2.9 degrees C, tumor IFP decreased to 3.2 +/- 1.1 mmHg, and efflux half-time increased to 13.5 min. Dexamethasone decreased IFP to 2.4 +/- 1.0 mmHg and increased efflux half-time to 15.4 min. Combined hypothermia and dexamethasone further increased the efflux half-time to 17.6 min. We tried to lower the tumor temperature by chilling the infusion solution, but at an infusion rate of 48 mul/min, the efflux rate was the same for room temperature saline and 15 degrees C saline. The efflux rate was increased in both infusion groups, which suggests that efflux due to tumor IFP and that of the infusate were additive. Since lowering tumor IFP decreases efflux from brain tumors, it provides a means to increase drug residence time, which in turn increases the time-concentration exposure product of therapeutic drug available to tumor.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16775223      PMCID: PMC1871948          DOI: 10.1215/15228517-2006-007

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  37 in total

1.  Hypothermic circulatory arrest is not a risk factor for neurologic morbidity in aortic surgery: a propensity score analysis.

Authors:  Takashi Kunihara; Timo Grün; Diana Aicher; Frank Langer; Oliver Adam; Olaf Wendler; Yasuaki Saijo; Hans-Joachim Schäfers
Journal:  J Thorac Cardiovasc Surg       Date:  2005-09       Impact factor: 5.209

2.  Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy.

Authors:  Seetha Shankaran; Abbot R Laptook; Richard A Ehrenkranz; Jon E Tyson; Scott A McDonald; Edward F Donovan; Avroy A Fanaroff; W Kenneth Poole; Linda L Wright; Rosemary D Higgins; Neil N Finer; Waldemar A Carlo; Shahnaz Duara; William Oh; C Michael Cotten; David K Stevenson; Barbara J Stoll; James A Lemons; Ronnie Guillet; Alan H Jobe
Journal:  N Engl J Med       Date:  2005-10-13       Impact factor: 91.245

3.  Mild intraoperative hypothermia during surgery for intracranial aneurysm.

Authors:  Michael M Todd; Bradley J Hindman; William R Clarke; James C Torner
Journal:  N Engl J Med       Date:  2005-01-13       Impact factor: 91.245

4.  Isolation of drug delivery from drug effect: problems of optimizing drug delivery parameters.

Authors:  Mir J Ali; Yot Navalitloha; Michael W Vavra; Eric W-Y Kang; Andrea C Itskovich; Peter Molnar; Robert M Levy; Dennis R Groothuis
Journal:  Neuro Oncol       Date:  2006-03-08       Impact factor: 12.300

5.  Comparative pharmacokinetics of 14C-sucrose in RG-2 rat gliomas after intravenous and convection-enhanced delivery.

Authors:  Michael Vavra; M Jaffer Ali; Eric W-Y Kang; Yot Navalitloha; Allison Ebert; Cathleen V Allen; Dennis R Groothuis
Journal:  Neuro Oncol       Date:  2004-04       Impact factor: 12.300

6.  Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy.

Authors:  Kristian Pietras; Kristofer Rubin; Tobias Sjöblom; Elisabeth Buchdunger; Mats Sjöquist; Carl-Henrik Heldin; Arne Ostman
Journal:  Cancer Res       Date:  2002-10-01       Impact factor: 12.701

7.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.

Authors:  Christopher G Willett; Yves Boucher; Emmanuelle di Tomaso; Dan G Duda; Lance L Munn; Ricky T Tong; Daniel C Chung; Dushyant V Sahani; Sanjeeva P Kalva; Sergey V Kozin; Mari Mino; Kenneth S Cohen; David T Scadden; Alan C Hartford; Alan J Fischman; Jeffrey W Clark; David P Ryan; Andrew X Zhu; Lawrence S Blaszkowsky; Helen X Chen; Paul C Shellito; Gregory Y Lauwers; Rakesh K Jain
Journal:  Nat Med       Date:  2004-01-25       Impact factor: 53.440

8.  Dexamethasone effects on vascular volume and tissue hematocrit in experimental RG-2 gliomas and adjacent brain.

Authors:  H Nakagawa; D R Groothuis; E S Owens; C S Patlak; K D Pettigrew; R R Glasberg
Journal:  J Neurooncol       Date:  1988-09       Impact factor: 4.130

9.  Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration.

Authors:  Flavio Curnis; Angelina Sacchi; Angelo Corti
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

10.  Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy.

Authors:  Alexei V Salnikov; Vegard V Iversen; Markus Koisti; Christian Sundberg; Lars Johansson; Linda B Stuhr; Mats Sjöquist; Håkan Ahlström; Rolf K Reed; Kristofer Rubin
Journal:  FASEB J       Date:  2003-07-18       Impact factor: 5.191

View more
  16 in total

1.  Perspective: Flicking with flow: Can microfluidics revolutionize the cancer research?

Authors:  Tamal Das; Suman Chakraborty
Journal:  Biomicrofluidics       Date:  2013-01-31       Impact factor: 2.800

2.  Compression stiffening of brain and its effect on mechanosensing by glioma cells.

Authors:  Katarzyna Pogoda; LiKang Chin; Penelope C Georges; FitzRoy J Byfield; Robert Bucki; Richard Kim; Michael Weaver; Rebecca G Wells; Cezary Marcinkiewicz; Paul A Janmey
Journal:  New J Phys       Date:  2014-07       Impact factor: 3.729

Review 3.  Surgical management of high-grade glioma: a standard of care.

Authors:  Colin Watts
Journal:  CNS Oncol       Date:  2012-11

4.  Polymer micelles with hydrazone-ester dual linkers for tunable release of dexamethasone.

Authors:  Melissa D Howard; Andrei Ponta; Allison Eckman; Michael Jay; Younsoo Bae
Journal:  Pharm Res       Date:  2011-05-26       Impact factor: 4.200

5.  Increased extracellular pressure stimulates tumor proliferation by a mechanosensitive calcium channel and PKC-β.

Authors:  Marc D Basson; Bixi Zeng; Christina Downey; Madhu P Sirivelu; Jetze J Tepe
Journal:  Mol Oncol       Date:  2014-10-23       Impact factor: 6.603

Review 6.  Integrating nanomedicine into clinical radiotherapy regimens.

Authors:  Allison N DuRoss; Megan J Neufeld; Shushan Rana; Charles R Thomas; Conroy Sun
Journal:  Adv Drug Deliv Rev       Date:  2019-07-04       Impact factor: 15.470

7.  DNA alkylation products formed by 1-(2-chloroethyl)-1-nitrosourea as molecular dosimeters of therapeutic response.

Authors:  William J Bodell
Journal:  J Neurooncol       Date:  2008-11-02       Impact factor: 4.130

Review 8.  Targeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the blood-brain barrier divide.

Authors:  Ann-Marie Chacko; Chunsheng Li; Daniel A Pryma; Steven Brem; George Coukos; Vladimir Muzykantov
Journal:  Expert Opin Drug Deliv       Date:  2013-06-11       Impact factor: 6.648

Review 9.  Mechanical Forces in Tumor Angiogenesis.

Authors:  Matthew R Zanotelli; Cynthia A Reinhart-King
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

10.  Chemoprotection Across the Tumor Border: Cancer Cell Response to Doxorubicin Depends on Stromal Fibroblast Ratios and Interstitial Therapeutic Transport.

Authors:  Daniel K Logsdon; Garrett F Beeghly; Jennifer M Munson
Journal:  Cell Mol Bioeng       Date:  2017-08-02       Impact factor: 2.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.